# Combination of PSA density and MLR improves the diagnostic accuracy of prostate cancer

**Authors:** Feng Guo, Aerken Maolake, Zecheng Ni, Xun Li, Bide Liu, Zetian Tang, Zhenfeng Shi, Jiuzhi Li

PMC · DOI: 10.3389/fonc.2025.1570584 · Frontiers in Oncology · 2025-07-16

## TL;DR

Combining PSA density and MLR improves prostate cancer diagnosis accuracy in patients with PSA levels between 4.0 and 22.0 ng/mL.

## Contribution

A new model combining PSA density and MLR is proposed to enhance prostate cancer detection accuracy.

## Key findings

- PSAD performed better than f/t PSA and PV in diagnosing prostate cancer.
- Combining PSAD and MLR increased AUC and improved positive predictive values in different PSA ranges.
- The specificity of PSAD was higher than f/t PSA in the PSA gray zone (4–10 ng/mL).

## Abstract

Prostate-specific antigen (PSA) is used to screen for prostate cancer for decades. However, PSA has poor specificity in prostate cancer screening within the 4.0- to 10.0-ng/mL range. This study aimed to develop a new prediction model for PCa in patients with a PSA level of 2.5–20 ng/mL. The clinical data of 80 patients with PSA 4–22 ng/mL from 2016 to 2022 were selected for retrospective analysis. Prostate volume was estimated by suprapubic ultrasonography. PSA and the inflammatory markers like neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) in peripheral blood were analyyzed to assess their value in PCa. The diagnostic performance of PSA, PSA density (PSAD), and inflammatory markers, respectively, was estimated by ROC curve. The areas under the ROC curve for f/t PSA, PV, PSAD, MLR, NLR, and PLR for predicting PCa in patients with a PSA level of 4.0–22.0 ng/mL were 0.7375, 0.7774, 0.8294, 0.5945, 0.5571, and 0.5437, respectively. The PSAD performed better than f/t PSA and PV in the diagnosis of PCa. The specificity of PSAD was higher than that of f/tPSA when tPSA was in the gray zone (between 4 and 10 ng/mL). The area under the curve (AUC) increased when PSAD was combined with MLR in patients with PSA 4–10 ng/mL and patients with PSA 10–22 ng/mL, and the positive predictive values were 81.81% and 90.91%, respectively (P = 0.0008 and P = 0.0002). PSAD has a moderate diagnostic value for PCa detection. The combination of PSAD and MLR could improve the diagnostic accuracy in PCa diagnosis.

## Linked entities

- **Proteins:** KLK3 (kallikrein related peptidase 3)
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}
- **Diseases:** NLR (MESH:D015467), metastasis (MESH:D009362), deaths (MESH:D003643), cancer (MESH:D009369), Inflammatory (MESH:D007249), PCa (MESH:D011471), PSAD (MESH:D011472), BPH (MESH:D011470)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12310160/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12310160/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12310160/full.md

---
Source: https://tomesphere.com/paper/PMC12310160